Overview
- 9 inspections across 9 sites are on record.
- 2 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2020-01-17.
At a glance
Inspections
9
Sites
9
Observations
2
Career since
Jan 2016
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 17 Jan 2020 | Human Drugs | |
| Celerion Inc | 11 Jan 2019 | Human Drugs | |
| BioAgilytix Labs LLC | 27 Jul 2018 | Human Drugs | |
| QPS, LLC | 8 Dec 2017 | Human Drugs | |
| Pra Health Sciences | 12 May 2017 | Human Drugs |
Sites inspected
Regeneron Pharmaceuticals IncTarrytown, United States1 insp.
Celerion IncLincoln, United States1 insp.
BioAgilytix Labs LLCDurham, United States1 insp.
QPS, LLCNewark, United States1 insp.
Pra Health SciencesAssen, Netherlands1 insp.
Co-investigators
Investigators who share inspections with this person.
Xikui Chen2 shared
Melkamu Getie Kebtie1 shared
Iram R Hassan1 shared
Vickie J Kanion1 shared
Elise A Murphy1 shared
Janete F Guardia1 shared
Yiyue Zhang1 shared
Karen L Kosar1 shared
Xiaohan Cai1 shared
Joseph L Despins1 shared
Full investigator report
Get the verbatim findings behind Michael F Skelly's 2 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site